Samenvatting
Personalized Medicine (PM) - the tailoring of medical treatment to the patient's individual characteristics - holds great promise for the future of healthcare. Low drug efficacy and the occurrence of adverse drug reactions hamper the current paradigm of medicine, which
relies mostly on a trial-and-error approach. Furthermore, the drug development industry is characterized by a high risk of failure, lengthy development cycles, huge investments and a declining R&D-productivity. Recent advancements in molecular biology have yielded a
number of successful applications whereby knowing a patient's molecular or genetic make-up (also called a biomarker) enables to determine the best-fitting treatment. As such, this personalized medicine transforms the health care value chain in critical areas such as research and development, market access and health care provision.
Existing literature on personalized medicine mainly analyzes factors external to the firm such as payer coverage, regulation and access. However, little attention is paid to some of the main strategic issues faced by companies developing and commercializing personalized
medicine applications. This paper addresses this research gap by investigating how and why drug developing companies access and integrate the (external) knowledge necessary for the development and marketing of these applications. The research question is formulated as follows: What influences the propensity of drug developing companies to engage in strategic alliances when developing and commercializing personalized medicine applications?
The aim of this paper is to build a theoretical framework on the strategic aspects of developing and commercializing a PM application. Firstly, we discuss PM and its impact on the development and commercialization strategies of pharmaceutical companies. Secondly,
we present a comprehensive literature review on the knowledge-based view on the firm, the appropriability regime theory and the role of strategic alliances in the pharmaceutical industry. This allows for the exploration of the link between knowledge, intellectual property
protection and future competition during the development and marketing of a PM application. Building on this literature, four expert interviews and several case studies, we build the proposed theoretical framework. It is proposed that the propensity to develop and market a personalized medicine application using strategic alliances and the nature of these alliances are influenced by the (1) the drug developing company's knowledge base on molecular diagnostics; and (2) the level of appropriability on the biomarker (in terms of intellectual property (IP) protection and degree of novelty).
The results of this research may contribute to managers' and policy makers' understanding of how and why collaborations in the field of PM exist. Such knowledge allows for better decision-making processes on how to structure drug developing companies in a way that they can more easily tackle the many challenges in the field of Personalized Medicine.
relies mostly on a trial-and-error approach. Furthermore, the drug development industry is characterized by a high risk of failure, lengthy development cycles, huge investments and a declining R&D-productivity. Recent advancements in molecular biology have yielded a
number of successful applications whereby knowing a patient's molecular or genetic make-up (also called a biomarker) enables to determine the best-fitting treatment. As such, this personalized medicine transforms the health care value chain in critical areas such as research and development, market access and health care provision.
Existing literature on personalized medicine mainly analyzes factors external to the firm such as payer coverage, regulation and access. However, little attention is paid to some of the main strategic issues faced by companies developing and commercializing personalized
medicine applications. This paper addresses this research gap by investigating how and why drug developing companies access and integrate the (external) knowledge necessary for the development and marketing of these applications. The research question is formulated as follows: What influences the propensity of drug developing companies to engage in strategic alliances when developing and commercializing personalized medicine applications?
The aim of this paper is to build a theoretical framework on the strategic aspects of developing and commercializing a PM application. Firstly, we discuss PM and its impact on the development and commercialization strategies of pharmaceutical companies. Secondly,
we present a comprehensive literature review on the knowledge-based view on the firm, the appropriability regime theory and the role of strategic alliances in the pharmaceutical industry. This allows for the exploration of the link between knowledge, intellectual property
protection and future competition during the development and marketing of a PM application. Building on this literature, four expert interviews and several case studies, we build the proposed theoretical framework. It is proposed that the propensity to develop and market a personalized medicine application using strategic alliances and the nature of these alliances are influenced by the (1) the drug developing company's knowledge base on molecular diagnostics; and (2) the level of appropriability on the biomarker (in terms of intellectual property (IP) protection and degree of novelty).
The results of this research may contribute to managers' and policy makers' understanding of how and why collaborations in the field of PM exist. Such knowledge allows for better decision-making processes on how to structure drug developing companies in a way that they can more easily tackle the many challenges in the field of Personalized Medicine.
| Originele taal-2 | English |
|---|---|
| Tijdschrift | Conference proceedings IAMB |
| Volume | 13 |
| Status | Published - 13 sep 2012 |
| Evenement | 13th IAMB Conference - , Indonesia Duur: 12 sep 2012 → 14 sep 2012 |